Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9%

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 2,770,000 shares, a decrease of 12.9% from the December 15th total of 3,180,000 shares. Currently, 3.7% of the company’s shares are sold short. Based on an average daily trading volume, of 309,000 shares, the short-interest ratio is presently 9.0 days.

Atea Pharmaceuticals Stock Up 1.2 %

AVIR stock traded up $0.04 during trading on Friday, reaching $3.37. 337,674 shares of the stock were exchanged, compared to its average volume of 485,999. Atea Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $4.60. The firm’s 50 day moving average is $3.25 and its 200 day moving average is $3.46.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.13. During the same quarter in the prior year, the business posted ($0.40) EPS. On average, research analysts expect that Atea Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the transaction, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 17.80% of the company’s stock.

Institutional Investors Weigh In On Atea Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Almitas Capital LLC bought a new stake in Atea Pharmaceuticals during the 2nd quarter worth approximately $4,271,000. BML Capital Management LLC boosted its position in shares of Atea Pharmaceuticals by 4.3% during the third quarter. BML Capital Management LLC now owns 6,650,000 shares of the company’s stock valued at $22,278,000 after buying an additional 274,379 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Atea Pharmaceuticals by 55.2% during the second quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company’s stock worth $1,968,000 after buying an additional 211,428 shares in the last quarter. Marshall Wace LLP purchased a new stake in Atea Pharmaceuticals in the 2nd quarter valued at $603,000. Finally, FMR LLC lifted its stake in Atea Pharmaceuticals by 2.8% during the 3rd quarter. FMR LLC now owns 6,618,297 shares of the company’s stock valued at $22,171,000 after acquiring an additional 182,174 shares in the last quarter. Institutional investors and hedge funds own 86.67% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.